MIR4711: A Drug Target / Disease Biomarker (G100616409)
MIR4711: A Drug Target / Disease Biomarker
MIR4711, also known as interleukin-4 receptor 711, is a protein that is expressed in various tissues throughout the body. It is a member of the interleukin-4 receptor family, which is a protein that is involved in the regulation of immune and inflammatory responses. MIR4711 is highly expressed in the skin, and has been shown to play a role in the development and progression of various skin diseases, including cancer.
One of the key functions of MIR4711 is its role in the regulation of skin cell proliferation. MIR4711 has been shown to promote the growth and differentiation of skinocytes, which are the cells that produce the skin, and it has been shown to play a role in the regulation of cell proliferation and apoptosis.
MIR4711 has also been shown to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of immune responses, and to contribute to the development of inflammatory diseases such as cancer.
In addition to its role in skin cell proliferation and inflammation, MIR4711 has also been shown to play a role in the regulation of pain. It has been shown to contribute to the development and progression of pain conditions, and to play a role in the regulation of pain perception.
Overall, MIR4711 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in the regulation of skin biology and disease.
Protein Name: MicroRNA 4711
The "MIR4711 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4711 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR4712 | MIR4713 | MIR4713HG | MIR4714 | MIR4715 | MIR4716 | MIR4717 | MIR4718 | MIR4720 | MIR4721 | MIR4722 | MIR4723 | MIR4724 | MIR4725 | MIR4726 | MIR4727 | MIR4728 | MIR4729 | MIR4730 | MIR4731 | MIR4732 | MIR4733 | MIR4734 | MIR4735 | MIR4736 | MIR4737 | MIR4738 | MIR4739 | MIR4740 | MIR4741 | MIR4742 | MIR4745 | MIR4746 | MIR4747 | MIR4749 | MIR4750 | MIR4751 | MIR4752 | MIR4753 | MIR4754 | MIR4755 | MIR4756 | MIR4757 | MIR4758 | MIR4759 | MIR4760 | MIR4761 | MIR4762 | MIR4763 | MIR4764 | MIR4765 | MIR4766 | MIR4767 | MIR4768 | MIR4769 | MIR4770 | MIR4771-1 | MIR4771-2 | MIR4772 | MIR4773-1 | MIR4773-2 | MIR4774 | MIR4775 | MIR4776-1 | MIR4776-2 | MIR4777 | MIR4778 | MIR4779 | MIR4780 | MIR4781 | MIR4782 | MIR4783 | MIR4784 | MIR4785 | MIR4786 | MIR4787 | MIR4789 | MIR4790 | MIR4791 | MIR4793 | MIR4794 | MIR4795 | MIR4796 | MIR4797 | MIR4798 | MIR4799 | MIR4800 | MIR4802 | MIR4803 | MIR4804 | MIR483 | MIR484 | MIR485 | MIR486-1 | MIR486-2 | MIR487A | MIR487B | MIR488 | MIR489 | MIR490
